Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets

Overview

This study evaluates the use of ascorbic acid, vitamin C, to temporary reduce gastric pH in individuals with omeprazole induced hypochlorhydia. All participants will receive ascorbic acid tablets to measure the change in gastric pH.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 15, 2023

Detailed Description

Elevation of gastric pH in patients with hypochlorhydria can reduce the solubility of weakly basic drugs. This may lead to poor and unpredictable systemic exposure for poorly soluble drugs. For example, extent of absorption of the kinase inhibitors, dasatinib (Sprycel) and erlotinib (Tarceva), is reduced by up to 61% and 46% respectively in patients on acid-reducing agents (ARAs). This pilot study is to evaluate the use of ascorbic acid, vitamin C, to temporary reduce gastric pH in individuals with omeprazole induced hypochlorhdyria. Using pH/impedance testing, we are seeking to determine the magnitude and duration of pH change upon administration of 1000 mg of ascorbic acid in healthy subjects with proton-pump inhibitor induced hypochlorhydria. The results from this study will be used to evaluate the use of ascorbic acid as a drug-drug interaction mitigation strategy.

Interventions

  • Drug: Omeprazole 20mg
    • Omeprazole twice daily x 5 days
  • Dietary Supplement: Vitamin C
    • Ascorbic acid x 1 on day 5

Arms, Groups and Cohorts

  • Experimental: Experimental: omeprazole and ascorbic acid

Clinical Trial Outcome Measures

Primary Measures

  • Change in gastric pH and duration of gastric pH \status
    • Time Frame: Five hours
    • Gastric pH measurements will be continuously monitored throughout the study using a catheter-based pH monitoring system. Gastric pH versus time data will be collected for five hours.

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy, young males age 18-30 years with no prior history of gastrointestinal disease or symptoms. Exclusion Criteria:

  • Hypochlorhydria (baseline use antacids, antisecretory medications, or surface agents including proton-pump inhibitors, H2 blockers, or sucralfate). – Current or previous history of gastrointestinal disease including gastroesophageal reflux disease, Barrett's esophagus, peptic ulcer disease, dyspepsia, gastroparesis, bacterial overgrowth, microscopic colitis, gastric intestinal metaplasia or metaplastic atrophic gastritis, gastric neuroendocrine tumors, helicobacter pylori infection, inflammatory bowel disease (Crohn's disease or ulcerative colitis), celiac disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled thyroid disease, history of liver disease). – History of gastric bypass or other abdominal surgeries excluding cholecystectomy or appendectomy > 6 months prior to study initiation. – Radiation therapy to the abdomen. – Pregnant females. – Ingestion of any prescription, over-the-counter, or herbal medications which may affect study interpretation. – Currently a smoker – Antibiotic use within the last 3 months

Gender Eligibility: Male

Biological males

Minimum Age: 18 Years

Maximum Age: 30 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Indiana University
  • Collaborator
    • Hala Fadda
  • Provider of Information About this Clinical Study
    • Principal Investigator: Andrea Shin, Assistant Professor – Indiana University
  • Overall Contact(s)
    • Alka Kadariya, 317-278-9296, akadariy@iu.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.